Improved patient access
The first personalized ctDNA test to inform adjuvant treatment decisions and detect recurrence earlier
When Is Signatera Used?
Our commitment is to improve patient access to personalized and tumor-informed testing to help guide treatment decisions. Signatera is a tool that allows physicians to stratify their patients, closely monitor the effectiveness of adjuvant therapy and detect early relapse better than conventional tools. Signatera is a custom-built and tumor informed molecular residual disease (MRD) assay used to inform the presence of circulating tumor DNA (ctDNA), enabling physicians to get in front of disease or provide patients with much-needed peace of mind.
- Risk Stratification
After surgical resection to inform adjuvant treatment decisions
- Recurrence monitoring
To find early signs of cancer recurrence in patients with a previous cancer diagnosis
- Therapeutic response
To monitor the cancer’s response to treatment like immunotherapy (IO) on a molecular level
Natera accepts all commercial and public insurances
- Benefits include serial use of Signatera in patients with stages II/III colorectal cancer(CRC)1
- Benefits also include single time point use for patients with stages II/III colorectal cancer(CRC)
- Medicare patients with staged II/III CRC are fully covered, other indications are welcome however an ABN may be required*
- Patients on immunotherapy will be covered for serial use of Signatera
Please note, Altera testing is covered only if the Altera NGS test has not been previously ordered for the patient’s same primary diagnosis of cancer.
Reach out to Natera for support with coverage
- We welcome all insurance plans
- We will work with patients so that cost is not a barrier for testing
- We offer an affordable cash pay rate for those patients who do not wish to use insurance
1Reinert T, Henriksen TV, Christensen E, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 2019;5(8):1124–1131
2Bratman SV, Yang SYC, Iafolla MAJ, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat. Cancer. 2020